Structured Care During Recurrent Fever: Evidence-Based Approaches for Clinical Practice

Abstract

Recurrent fever syndromes present a complex clinical challenge, requiring structured and systematic care to optimize patient outcomes. This article reviews the current epidemiology, pathophysiology, risk factors, clinical features, diagnostic protocols, and management strategies for recurrent fever, with a focus on evidence-based approaches and recent advances. Emphasis is placed on integrating guideline recommendations and clinical insights to aid healthcare professionals in delivering comprehensive care to patients with recurrent fever patterns.

Introduction

Recurrent fever, defined as repeated episodes of elevated body temperature separated by afebrile intervals, is a common yet diagnostically challenging presentation in both pediatric and adult populations. The etiological spectrum is broad, encompassing infectious, autoinflammatory, autoimmune, and neoplastic disorders. A structured approach to care is critical for timely diagnosis, risk stratification, and initiation of appropriate therapy. Recent guideline updates and emerging evidence have refined the clinical management of recurrent fever syndromes, underscoring the importance of multidisciplinary collaboration and individualized care pathways.

Epidemiology / Disease Burden

The true incidence and prevalence of recurrent fever varies by age group, geographic location, and underlying etiology. Autoinflammatory syndromes, such as familial Mediterranean fever (FMF) and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA), are most commonly identified in children, with FMF having a higher prevalence in Mediterranean populations. Infectious causes, including malaria and tuberculosis, remain significant contributors globally, particularly in endemic regions. The diagnostic journey for patients with recurrent fever can be lengthy, often resulting in repeated healthcare utilization, unnecessary investigations, and delayed treatment. This disease burden highlights the necessity for structured clinical pathways to reduce morbidity and optimize resource utilization.

Pathophysiology

The mechanisms underlying recurrent fever are diverse and depend on the primary etiology. Autoinflammatory syndromes are characterized by dysregulation of the innate immune system with inappropriate activation of inflammasomes and excessive cytokine production, notably interleukin-1β. In contrast, autoimmune conditions involve aberrant adaptive immune responses with autoantibody formation and immune complex deposition. Infections leading to recurrent fever may result from persistent pathogens, immune evasion, or incomplete initial treatment. Neoplastic causes, such as lymphoma, may provoke fever through cytokine release or paraneoplastic phenomena. Understanding these mechanisms is imperative for targeted diagnostic and therapeutic interventions.

Risk Factors

Risk stratification is essential in the evaluation of recurrent fever. Genetic predispositions, such as mutations in the MEFV gene for FMF, play a pivotal role in autoinflammatory syndromes. Epidemiological factors—including geographic origin, exposure history, and family history—can guide differential diagnosis. Immunocompromised states, including primary immunodeficiencies and iatrogenic immunosuppression, increase susceptibility to recurrent infections. Additionally, environmental exposures and travel history may uncover rare infectious etiologies. Comprehensive risk assessment underpins effective clinical triage and tailored management.

Clinical Features

The clinical presentation of recurrent fever syndromes is heterogeneous. Common features include periodic high-grade fevers, malaise, and systemic symptoms such as rash, arthralgia, lymphadenopathy, and mucosal ulcers. In FMF, fever episodes are often accompanied by serositis, while PFAPA is characterized by regular fever attacks, pharyngitis, and cervical adenitis. Infections may present with organ-specific signs or constitutional symptoms. Careful documentation of fever patterns, associated symptoms, and inter-episode well-being is critical for narrowing the diagnostic possibilities.

Diagnosis

Diagnosis of recurrent fever requires a systematic, stepwise approach integrating clinical history, physical examination, and targeted investigations. Initial laboratory workup should include complete blood count, inflammatory markers (CRP, ESR), liver and renal function tests, and cultures as indicated. Genetic testing is warranted in suspected autoinflammatory syndromes. Imaging studies may be necessary for evaluation of deep-seated infections or neoplastic processes. Diagnostic criteria, such as the Tel Hashomer criteria for FMF and Marshall\'s criteria for PFAPA, aid in standardizing diagnosis. Exclusion of malignancy and immunodeficiency is paramount in persistent or atypical cases.

Treatment & Management

Management strategies are dictated by the underlying etiology. Autoinflammatory syndromes often respond well to colchicine (FMF) or corticosteroids (PFAPA). Biologic agents targeting interleukin-1 (anakinra, canakinumab) have revolutionized care in refractory cases. Infectious causes necessitate pathogen-specific antimicrobial therapy, while autoimmune conditions may require immunosuppressive agents. Supportive care, including antipyretics and hydration, remains foundational. Patient education, regular follow-up, and multidisciplinary coordination are essential for long-term disease control and prevention of complications.

Recent Advances / Emerging Therapies

The advent of next-generation sequencing has facilitated the identification of novel genetic mutations underlying recurrent fever syndromes, enabling precision medicine approaches. The introduction of IL-1 inhibitors has significantly improved outcomes in patients with colchicine-resistant FMF and other autoinflammatory disorders. Ongoing clinical trials are evaluating additional biologic targets, such as IL-6 and TNF-α inhibitors. Advances in diagnostic algorithms, including machine learning-based decision support, are enhancing early recognition and individualized management of recurrent fever.

Guideline Recommendations

Recent guidelines from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) emphasize an algorithmic approach to recurrent fever, advocating for early genetic testing in high-risk populations and prompt initiation of disease-modifying therapies. Regular monitoring for organ involvement and treatment-related adverse effects is recommended. Multidisciplinary collaboration, involving rheumatology, infectious disease, immunology, and genetics, is vital for optimal patient care. Guidelines also highlight the importance of patient and family education to improve adherence and quality of life.

Conclusion

Structured care is paramount in the evaluation and management of recurrent fever, given its diverse etiologies and significant disease burden. An evidence-based, multidisciplinary approach—anchored in recent guidelines and emerging scientific advances—can improve diagnostic accuracy, expedite effective therapy, and enhance patient outcomes. Continued research into the molecular mechanisms and therapeutic targets of recurrent fever syndromes promises further improvements in individualized care pathways for affected patients.